Table 1.

Clinical and Pathological Characteristics

Patient	Age at DX	R/E	Classification	Grade	Size of 1° (cm)	Adjuvant Chemo	Recurrence	Follow-up (mo)	Current Status
1	52	C	chondroid	3	9	AC	lung, bone, brain in 7 mo	12	deceased
2	31	AA	chondroid	3	4.9	AC	no	182	NED
3	60	C	fibromatosis	2	3.1	C/T	lung at 6 years	168	NED
4	64	C	mesenchymal NOS	3	5	C/T	no	173	NED
5	57	C	chondroid	3	9	AC	bone in 26 mo	27	deceased
6	68	C	fibromatosis	1	1.5	none	local at 2 years	102	NED
7	64	C	squamous*	3	1.4	none	no	41	deceased
8	47	C	chondroid	3	3.5	XT-AC(neo); C/T	local at 4 years	117	NED
9	69	H	osseous	3	2.5	C/T	no	120	NED
10	56	AA	chondroid	3	3	AC	no	111	NED
11	50	C	chondroid	3	5.5	AC-T	no	113	NED
12	40	H	mesenchymal NOS	3	2.3	C/T	no	103	NED
13	67	C	spindle cell	3	1.2	AC	no	100	NED
14	44	C	mesenchymal NOS	3	3	C/T	no	85	NED
15	34	H	chondroid	3	2.5	TC	no	86	NED
16	61	C	chondroid	3	1.1	C/T	no	88	NED
17	56	C	chondroid	3	2.3	C/T	no	91	NED
18	64	C	chondroid	3	0.7	TC	no	69	NED
19	46	C	chondroid	3	5.3	TCH	no	61	NED
20	68	C	squamous	3	3.1	TC	no	70	NED
21	57	C	squamous+chondroid	2	4.1	AC-T(neo)	lung in 6 mo	10	deceased
22	51	C	metaplastic NOS	3	3.3	AC-T(neo)	brain in 19 mo	23	deceased
23	40	AA	Chondroid**	3	3	AC-T(neo)	lung, bone, brain in 15 mo	23	deceased

^*non-metaplastic portion of tumor was estrogen receptor positive

^**Post-neoadjuvant treatment tumor was erbB-2(HER2) positive

Abbreviations: Age at Dx = age at breast cancer diagnosis; R/E = race/ethnicity; C = Caucasian; H = Hispanic; AA = African American; Size of 1° = size of primary tumor at presentation. Chemo = adjuvant chemotherapy; neo = neoadjuvant chemotherapy; C/T = carboplatin and paclitaxel; TCH = docetaxel, carboplatin and trastuzumab; AC = doxorubicin and cyclophosphamide; TC = docetaxel and cyclophosphamide; XT=capecitabine and docetaxel; AC-T = doxorubicin and cyclophosphamide followed by paclitaxel; NED = no evidence of disease; NOS = not otherwise specified